FDA approve nivolumab plus ipilimumab for first line treatment of metastatic or recurrent non-small-cell lung cancer

Approval was based on the phase 3 CheckMate -9LA trial which reported that this combined therapy demonstrated superior overall survival vs chemotherapy alone (14.1 vs. 10.7 months; HR 0.69; 95% CI,0.55 to 0.87, p=0.0006) regardless of PD-L1 expression or tumour histology


Biospace Inc.